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Abstract
The nuclear bile acid receptor FXR (farnesoid-X-receptor)
has recently been implicated in the pathophysiology of non-
alcoholic fatty liver disease because selective FXR-agonists
improve glucose and lipid metabolism in rodent models of
obesity. However, the regulation of FXR and other relevant
nuclear receptors as well as their lipogenic target genes in
fatty liver is still not revealed in detail. Livers were harvested
from 14-week-old male ob/ob mice and wild-type controls.
Serum bile acids were quantified by radioimmunoassay.
mRNA and protein expression of transporters and nuclear
receptors was analyzed by reverse transcriptase-polymerase
chain reaction and Western blotting, whereas DNA binding
to the IR-1 element was examined by electrophoretic mobil-
ity shift assay. In this study we show: (i) bile acid retention
in ob/ob mice, (ii) a resulting FXR upregulation and binding
to the IR-1 element in ob/ob animals and (iii) concomitant
activation of the fatty acid synthase as a potential lipogenic
FXR target gene in vivo. The present study suggests a poten-
tial role of hepatic bile acid retention and FXR activation in
the induction of lipogenic target genes. Differences between
intestinal and hepatic FXR could explain apparent contradic-
tory information regarding its effects on fatty liver disease.
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Introduction
Non-alcoholic fatty liver disease (NAFLD) is an increasingly
recognized condition that affects 10–24% of the general pop-
ulation and comprises liver disorders ranging from steatosis
and non-alcoholic steatohepatitis (NASH) to advanced fibro-
sis and cirrhosis (Angulo, 2002; Adams et al., 2005; Stefan
et al., 2008; Erickson, 2009). The increasing global burden
of obesity and related diseases highlights the necessity to
define targeted future strategies of intervention based on
pathophysiology.
Bile acids are physiological ligands of the nuclear bile acid
receptor FXR (farnesoid-X-receptor) that can be referred to
as an intracellular bile acid sensor which is the key regulator
in bile acid homeostasis (Makishima et al., 1999). Recent
studies in genetic mouse models of obesity and diabetes
(ob/ob and db/db mice) highlight a link between FXR acti-
vation and development of the metabolic syndrome because
treatment with its synthetic ligand GW4064 significantly
improves insulin sensitivity (Cariou et al., 2006; Zhang et
al., 2006). Hepatocellular bile acid retention is mainly caused
by reduced canalicular bile salt secretion as the rate-limiting
step in transport. Decreased expression of canalicular trans-
porters including the bile-salt export pump (BSEP/Bsep;
encoded by ABCB11) and the conjugate export pump (mul-
tidrug resistance-associated protein; MRP2/Mrp2, encoded
by ABCC2) have been described in various form of chole-
stasis (reviewed in Geier et al., 2007) and also in rodent
models of fatty liver disease and diabetes (Pizarro et al.,
2004; Geier et al., 2005b). As an adaptive response, accu-
mulating bile acids mediate indirect negative feedback reg-
ulation of hepatocellular bile acid uptake transporters such
as the high-affinity Naq-dependent bile-salt transporter
NTCP/Ntcp (encoded by SLC10A1) by an FXR-dependent
activation of the transcriptional repressor small heterodimer
partner (Shp) (Geier et al., 2007). Furthermore, bile acid-
activated FXR represents a negative transcriptional regulator
of cholesterol 7-a-hydroxylase (CYP7A1) expression, which
represents the rate-limiting enzyme in the de novo synthesis
of bile acids from cholesterol (reviewed in Chiang, 2009).
Interestingly, general FXR-/- mice not only exhibit elevated
serum bile acid concentrations but also develop fatty liver
which is severely aggravated when fed a 1% cholesterol diet
(Sinal et al., 2000; Lambert et al., 2003). Several reports
confirm an inverse correlation between bile acid-dependent
FXR-pathway activation and plasma triglyceride levels
because bile acid-feeding in different models of hypertrigly-
ceridemia decreased de novo lipogenesis through down-
regulation of sterol regulatory element binding protein-1c
(SREBP-1c) resulting in reduced plasma triglycerides (Wata-
nabe et al., 2004; Bilz et al., 2006).
1442 I.V. Martin et al.
Article in press - uncorrected proof
Figure 1 Liver histology and expression of inflammatory cytokines in ob/ob mice.
(A) Representative hematoxylin and eosin staining of liver sections from wild-type and ob/ob mice (200=magnification). Accumulation of
hepatocellular lipid vacuoles are present in ob/ob livers (right) compared with wild-type livers with normal histological appearance (left).
(B) Analysis of inflammatory cytokine gene expression. Quantitative RT-PCR was performed with RNA samples isolated from liver of
controls and ob/ob-mice (ns6). The asterisk indicates p-0.05 as determined by Student’s t-test.
Despite the central role of FXR and other nuclear recep-
tors in bile acid and lipid metabolism, their endogenous
expression in fatty livers is still elusive. These nuclear recep-
tors undergo marked changes in their expression and activity
during cholestasis and inflammation (Trauner et al., 1998;
Denson et al., 2000; Geier et al., 2003; Ghose et al., 2004;
Geier et al., 2005b,c; Zollner et al., 2005) both of which are
characteristic of NAFLD also. We hypothesize that bile acid
accumulation in fatty livers leads to the activation of nuclear
receptors, particularly FXR, and respective target genes
under these specific conditions.
Therefore, the aim of this study was to characterize the
expression of FXR and other class II nuclear receptors in
fatty livers of ob/ob mice and to elucidate potential effects
of accumulating bile acids on lipogenic FXR-target genes
under these conditions.
Results
Ob/ob mice develop liver steatosis without
inflammation
Leptin-deficient ob/ob mice spontaneously developed hepatic
steatosis at 14 weeks of age. In these animals hematoxylin
and eosin staining of paraffin-embedded tissue sections dem-
onstrated a severe hepatic steatosis without signs of histo-
pathological inflammation compared with unaffected
wild-type controls (Figure 1A). The liver/body weight ratio
of 14-week-old ob/ob mice (9.0"0.2%) was increased in
comparison with wild-type controls (5.0"0.4%; ns6 each).
mRNA expression levels of proinflammatory cytokines are
increased in ob/ob-mice compared with control animals
w2.26"0.26-fold for interleukin (IL)-1b and 4.05"0.32-fold
for tumor necrosis factor-a (TNF-a), 3.19"0.74-fold for IL-
8, respectively; ns6; p-0.05 eachx. No change was observed
for IL-12 (data not shown) (Figure 1B).
Decreased bile acid transporter expression renders
fatty livers in ob/ob mice cholestatic
Whether ob/ob mice are cholestatic, as recently reported for
fa/fa Zucker rats, has not been investigated so far (Geier et
al., 2005a). Serum bile acid concentrations as measured by
radioimmunoassay (RIA) are increased sevenfold in ob/ob
mice in comparison with wild-type controls (14.9"5.4 vs.
1.9"1.0 mM; ns6; ps0.00080) (Figure 3).
Subsequently, hepatic bile salt and organic anion trans-
porter expression in ob/ob mice has been determined at both
mRNA and protein expression level using real-time reverse
transcriptase-polymerase chain reaction (RT-PCR) and West-
ern blot analysis (Figures 2 and 3). RNA expression of baso-
lateral uptake transporters was significantly decreased for
Oatp1a1 and Oatp1a4 (organic anion transporter) compared
with control mice to 2"1% and 55"6%, respectively. Sim-
ilarly, protein expression was reduced to 9"1% (Oatp1a1)
and 11"6% (Oatp1a4) (both p-0.05). Whereas Ntcp mRNA
expression was largely unchanged, Ntcp protein levels were
significantly decreased in ob/ob-mice compared with wild-
FXR in the pathogenesis of NAFLD in ob/ob-mice 1443
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Figure 2 Hepatic transporter gene expression is altered in ob/ob mice.
Quantitative TaqMan RT-PCR was performed with RNA samples isolated from liver of controls and ob/ob-mice (ns6). The asterisk indicates
p-0.05 as determined by Student’s t-test.
type controls (70"9%; p-0.05). In contrast to other baso-
lateral transporters, Oatp2b1 mRNA was significantly
increased to 188"30% of controls. Expression of basolateral
export systems was strongly upregulated at the mRNA (Mrp3
332"45%; Mrp4 1086"170%) and protein level (Mrp4
618"65%; p-0.05) each compared with controls.
On the contrary to other rodent models of cholestasis, but
similar to fa/fa rats, expression of canalicular transporters
was mainly decreased at the protein level. Whereas Bsep and
Mrp2 mRNA expression levels were even increased in
ob/ob mice to 234"40% and 168"16% of wild-type controls
(p-0.05) microsomal protein levels were decreased to
59"10% for Bsep and 67"16% for Mrp2 (p-0.05).
Consistent with decreased transporter protein abundance
and bile acid retention in cholestatic ob/ob mice Cyp7a1
mRNA expression is profoundly suppressed compared with
non-cholestatic lean animals to 10"4% (ps0.0001) (Figure
4A).
FXR and other nuclear receptors are upregulated in
ob/ob mice
In contrast to rodent models of inflammatory liver disease
nuclear receptor activity is not suppressed in obese fa/fa rats
(Geier et al., 2005a,b). To examine the influence of bile acid-
retention and induction of proinflammatory cytokines on
nuclear receptors in ob/ob mice, we analyzed both mRNA
and protein expression of several nuclear receptors implicat-
ed in bile acid-signaling including FXR, pregnane X receptor
(PXR) and vitamin D receptor (VDR) (Figure 4). Most prom-
inently, FXR nuclear protein was increased to 330"70%
(mRNA expression 196"21%) in ob/ob mice compared with
controls (p-0.05 each). VDR and PXR expression were sim-
ilarly increased at both nuclear protein (225"43% and
258"34%, respectively) and mRNA levels (309"27% and
130"26%, respectively). Likewise, liver X receptor (LXR)
protein and mRNA levels increased by 146"20% and
169"19% compared with the wild-type.
Finally, Shp mRNA and protein expression was analyzed
to determine whether FXR activation results in the induction
of this target gene. In contrast to other rodent models of
cholestasis, Shp mRNA and protein expression in ob/ob mice
were not significantly increased and comparable with their
control littermates (Figure 4A).
FXR DNA-binding activity and lipogenic target genes
including fatty acid synthase are increased in ob/ob
mice
To investigate whether the observed increase in FXR nuclear
protein results in increased DNA binding activity and acti-
vation of respective target genes, we analyzed binding to the
FXR-responsive element IR-1 which is present in mouse pro-
moters of the Bsep (bile-salt export pump) and Fas (fatty
acid synthase) gene (Ananthanarayanan et al., 2001; Mat-
sukuma et al., 2006). Using electrophoretic mobility shift
assays (EMSAs) DNA binding activity to the IR-1 element
is doubled in nuclear extracts from obese mice (196"3%
compared with lean controls; p-0.05) (Figure 5). Following
the trend of an increased mRNA expression of Bsep (see
Figure 2), FAS mRNA expression, another FXR target gene,
was upregulated to 4982"1432% (p-0.05) (Figure 6) con-
sistent with activated IR-1 binding.
As expected, other lipogenic genes including peroxisome
proliferator-activated receptor-g (PPAR-g) mRNA and its
target transcript Srebp-1c were upregulated in ob/ob mice
58-fold and seven-fold (both p-0.05 each), respectively
(Figure 6).
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Figure 3 Western blot analysis of hepatic transporter protein expression in ob/ob mice and serum bile acid concentration in ob/ob mice.
(A) Western blotting: microsomal protein of wild-type and ob/ob mice (ns6 each) was separated by SDS-PAGE (protein loading 50 mg/
lane), blotted onto a PVDF membrane and detected by specific antibodies. (B) Densitometric analysis: quantification of relative protein
expression compared with wild-type animals. The asterisk indicates p-0.05 as determined by Student’s t-test. (C) Serum from wild-type
and ob/ob animals was collected. Serum bile acids were measured by RIA. Asterisk indicates p-0.05 as determined by Student’s t-test.
Discussion
Previous evidence from obese fa/fa Zucker rats as an estab-
lished model of NAFLD, obesity and diabetes highlights the
possibility that bile acid retention could play a role in the
pathogenesis of the underlying metabolic disease (Pizarro et
al., 2004; Geier et al., 2005b). We now used the ob/ob mouse
model of fatty liver disease to further investigate potential
bile acid-mediated effects on nuclear receptor activity and
lipogenic target genes in more detail. This model resembles
human fatty liver disease without histological inflammatory
infiltrates and is characterized only by a subclinical extent
of intrahepatic cytokine activation. The major new findings
of the present study are: (i) the bile acid retention in ob/ob
mice rendering these animals by definition cholestatic,
(ii) the resulting FXR upregulation and binding to the IR-1
element in ob/ob animals and (iii) the concomitant activation
of the fatty acid synthase as lipogenic potential FXR target
gene in vivo.
In the current study, we describe bile acid retention and
FXR activation as a potential trigger in the pathogenesis of
fatty liver disease in ob/ob mice. This retention of bile acids
is well in accordance to preliminary data from human
patients with fatty liver disease which are also characterized
by an increase in serum bile acid concentrations (Aranha et
al., 2008; Kocabayoglu et al., 2009). Cholestasis in mice
FXR in the pathogenesis of NAFLD in ob/ob-mice 1445
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Figure 4 Nuclear receptor mRNA and protein expression in ob/ob mice.
(A) mRNA expression: quantitative TaqMan RT-PCR was performed with RNA samples isolated from liver of controls and ob/ob-mice
(ns6). (B) Western blot analysis: nuclear protein and whole cell extract (SHP) were separated by SDS-PAGE (protein loading 10 mg/lane),
blotted onto a PVDF membrane and detected by specific antibodies. (C) Densitometric analysis: quantification of relative protein expression
shown in B compared with wild-type mice. The asterisk indicates p-0.05 as determined by Student’s t-test.
with fatty livers is accompanied by a downregulation of can-
alicular bile acid transporter Bsep and Mrp2 proteins as the
rate-limiting step in bile acid secretion. Furthermore, there
seems to be a lack in the cholestatic feedback inhibition of
Ntcp in ob/ob mice (Figures 2 and 3). Differences between
maintained RNA expression and slightly decreased protein
levels could be explained by post-translational modification
or compartmental changes in protein location. A moderate
decrease in Ntcp and Bsep protein expression is in accor-
dance with previous observations in fa/fa rats (Pizarro et al.,
2004; Geier et al., 2005b). Dysregulation of NTCP is even
more prominent in humans where higher mRNA expression
levels have been linked to disease progression in human
NAFLD (Kocabayoglu et al., 2009). Of note, Cheng and co-
workers observed in ob/ob mice a decreased Ntcp (mRNA
and protein) and Bsep (mRNA) expression and an even
induced Mrp2 protein (mRNA unchanged compared with
lean controls) (Cheng et al., 2008) which do not parallel
other findings in humans (Martin et al., 2009), rats (Pizarro
et al., 2004; Geier et al., 2005b) and mice with fatty livers.
Discrepancies could be explained by different breeding con-
ditions which are particularly relevant owing to established
changes in the intestinal barrier of ob/ob mice leading to
changes in portal lipopolysaccharide levels that can contrib-
ute to hepatic inflammatory damage (Brun et al., 2007). Nev-
ertheless, Cheng et al. report similar alterations in the
expression of other basolateral bile acid transporters in
ob/ob mice including the downregulation of Oatp1a1 and the
induction of the overflow systems Mrp3 and Mrp4 in accor-
dance with the present study (Cheng et al., 2008).
The underlying molecular mechanisms leading to trans-
porter dysregulation might be different from (obstructive)
cholestasis. Hepatic FXR expression is upregulated in ob/ob
mice at both the mRNA and protein levels and, as expected,
in the presence of bile acid retention FXR binding to the
corresponding IR-1 element is activated (Figures 4 and 5).
This is in line with a transcriptional activation of the FXR
target gene Bsep via IR-1 binding but decreased Bsep protein
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Figure 5 DNA-binding activity of FXR to the corresponding
IR-1 element.
DNA-binding analysis was performed with nuclear proteins
obtained from liver tissue of control and ob/ob mice (ns4 each).
Nuclear protein was incubated with biotin-labeled oligonucleotides
representing the IR-1 element. Specificity of binding was confirmed
by inclusion of specific competitor (SC) oligonucleotide or an unre-
lated oligonucleotide at a 300-fold molar excess (NSCsnon-specific
competitor).
Figure 6 Hepatic mRNA expression of lipogenic genes in ob/ob
mice.
Quantitative TaqMan RT-PCR was performed with RNA samples
isolated from liver of controls and ob/ob-mice (ns6). Asterisk indi-
cates p-0.05 as determined by Student’s t-test.
necessitates the postulation of further post-translational pro-
cessing under these conditions (Figures 2, 3 and 5). How-
ever, we could not detect an upregulation of Shp as another
FXR-target, as previously shown for obstructive cholestasis
(Zollner et al., 2005) either on the mRNA or protein level.
These results regarding an absent Shp mRNA induction have
been previously reported in obese ob/ob and db/db mouse
models (Zhang et al., 2006; Miao et al., 2009). Miao and co-
workers could further demonstrate that Shp protein abun-
dance is highly controlled by ubiquitin-proteasomal
degradation in wild-type animals whereas ob/ob mice are
largely protected against Shp ubiquitination.
Irrespective of ameliorating effects of FXR activation on
hepatic inflammation, fibrosis during steatohepatitis and lipid
abnormalities in the mouse model (Cipriani et al., 2009;
Zhang et al., 2009) the activation of FXR could also play a
role for the dysregulation of lipogenesis in the pathogenesis
of fatty liver disease. Recently, a FXR-responsive element
(IR-1) has been identified within the mouse Fas promoter
which mediates a bile acid-dependent upregulation of the
Fas gene, in addition to the established insulin-induced acti-
vation (Wang and Sul, 1998; Matsukuma et al., 2006). In the
present study extremely high levels of Fas transcripts have
been observed in ob/ob mice in the presence of increased
IR-1 (FXR) binding (Figures 5 and 6). A moderately
increased Fas expression in both wild-type and obese
KK-Ay mice upon long-term feeding of cholic acid with a
concurrent decrease of Srebp-1 support this concept in gen-
eral (Watanabe et al., 2004).
Consistent with Fas activation the lipogenic transcription
factor Srepb-1c and its upstream activators LXR, PPARg and
PXR are increased at the mRNA level (Figures 4 and 6). In
primary mouse hepatocytes it has been shown that the acti-
vation of FXR by bile acids or synthetic agonists represses
the expression of Srebp-1c and its lipogenic target genes in
a Shp-dependent manner (Watanabe et al., 2004).
Under the special conditions present in the livers of ob/ob
mice, activation of hepatic FXR could therefore affect the
fatty acid homeostasis of hepatocytes, by activating FAS
expression additionally to established Srebp-1c effects.
It is important to note that the role of FXR in the complex
pathophysiological scenario of fatty liver disease is not con-
clusively clarified so far. Whereas a variety of data suggest
the potentially beneficial role of bile acids in treatment of
NAFLD one cannot yet unambiguously evaluate their use-
fulness (Orlando et al., 2007). Several interventional and
knockout studies demonstrated beneficial effects of FXR
activation. The general absence of FXR in vivo has profound
consequences on systemic lipid metabolism because general
Fxr-/- mice have increased serum triglycerides, cholesterol
and free fatty acids and develop fatty livers (Sinal et al.,
2000; Lambert et al., 2003; Ma et al., 2006). On one hand,
a inverse correlation between the activation of FXR path-
ways and plasma triglyceride levels exists because bile
acid-feeding in different models of hypertriglyceridemia
decreased de novo lipogenesis through downregulation of
Srebp-1c resulting in reduced plasma triglycerides (Watanabe
et al., 2004; Bilz et al., 2006). On the other hand, treatment
of hyperlipidemic hamsters did not significantly decrease
Srebp-1c expression despite a reduction in triglyceride syn-
thesis (Bilz et al., 2006) and hepatic Srebp-1c mRNA levels
are not increased in Fxr-/- mice as to be expected (Zhang et
al., 2004; Duran-Sandoval et al., 2005a,b; Lefebvre et al.,
2009).
Studies in db/db and ob/ob mice have shown that treat-
ment with the synthetic FXR-specific ligand GW4064 sig-
nificantly improves insulin sensitivity and reduces hepatic
lipid accumulation (Cariou et al., 2006; Zhang et al., 2006).
Treatment with the FXR agonist GW4064 significantly
represses hepatic CYP7A1 in mice with liver-specific dele-
tion of Fxr (DeltaL) but not in mice with intestinal deletion
of Fxr (DeltaIE), which opens the possibility that activation
FXR in the pathogenesis of NAFLD in ob/ob-mice 1447
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of FXR in intestine but not in the liver could mediate hepatic
effects of GW4064 (Kim et al., 2007). Keeping in mind that
GW4064 is characterized by a poor pharmacokinetic profile
with poor intestinal absorption into the circulation these stud-
ies do not necessarily rule out that hepatic FXR and its acti-
vation in fatty livers could play a causal role in the
pathophysiology of fatty liver disease. To finally answer this
question comparable studies using intestinal and liver spe-
cific FXR deletion in obese mice might be necessary.
In summary, our study opens the possibility that bile acid
retention could contribute to the development of fatty liver
disease. Understanding the multifaceted function of FXR in
lipid homeostasis might contribute to pathophysiological and
therapeutic concepts for a targeted treatment of fatty liver
disease in the future.
Materials and methods
Animals
Eight-week-old male ob/ob mice (B6.V-Lepob/J) and age- and gen-
der-matched control animals C57BL/6J were purchased from The
Jackson Laboratory (Bar Harbor, ME, USA). All mice were housed
in pathogen-free animal facilities under a standard 12-h light, 12-h
dark cycle with access to regular rodent chow and autoclaved tap
water ad libitum for 6 weeks. The mice were sacrificed, and most
of the liver tissue was immediately frozen in liquid nitrogen and a
small portion was immersion fixed in 4% formalin. Subsequently,
paraffin-embedded sections were analyzed after hematoxylin and
eosin staining for the degree of hepatic steatosis. The animals
received humane care and the study protocols were approved by the
local Government’s Animal Care Committee.
mRNA isolation and real-time RT-PCR
Total RNA was isolated from liver by standard phenol chloroform
extraction procedure using UltraspecTM (Biotecx Lab, Houston, TX,
USA) according to manufacturer’s instructions. mRNA was reverse-
transcribed to cDNA using the Transcriptor First Strand cDNA Syn-
thesis Kit (Roche, Mannheim, Germany). cDNA was used for
RT-PCR with SYBR Green Reagent (Invitrogen, Karlsruhe, Ger-
many) and specific primer pairs on a 7300 ABI PRISM Real-Time
PCR System and with ABI PRISM 7300 SDS software (Applied
Biosystems, Foster City, CA, USA). Cyp7a1 expression was ana-
lyzed using ABI TaqMan probes. Expression was normalized
against 18S. All primer sequences are available from the authors
upon request.
Western blotting
Nuclear and microsomal protein fractions were prepared as
described previously (Gartung et al., 1997). Similar amounts of
microsomal and nuclear protein (50 mg and 10 mg, respectively)
were separated by SDS-PAGE, transferred to a polyvinylidene flu-
oride (PVDF) membrane and probed with the following antibodies:
Oatp1a1 (Eckhardt et al., 1999), Oatp1a4 (Reichel et al., 1999),
Ntcp (Stieger et al., 1994), BSEP (Gerloff et al., 1998), Mrp2
(Madon et al., 2000), Mrp4 (Rius et al., 2003), FXR (SantaCruz,
CA, USA, clone Q-20, sc-1205), LXR (Abcam, Cambridge, UK,
ab-28478), PXR (SantaCruz, USA, clone A-20, sc-7737), VDR
(SantaCruz, USA, clone C-20, sc-1008), SHP (SantaCruz, USA,
clone Q-14, sc-15283). Na/K ATPase (Abcam, Cambridge, UK, ab-
7671) and b-actin (Sigma, St. Louis, MO, USA, A2066) antibodies
were used as loading control for microsomal and total protein. After
incubation with species-specific HRP-conjugated secondary anti-
body (Dako, Hamburg, Germany) immune complexes were detected
using the ECL detection kit (GE Healthcare, Freiburg, Germany).
Densitometric quantification of Western blots was performed using
Quantity One software (Bio-Rad, Munich, Germany).
Electrophoretic mobility shift assay
Nuclear protein extracts were prepared as described previously
(Geier et al., 2002). DNA binding analyses were conducted using
the Lightshift Chemiluminescent EMSA kit (Pierce Biotechnology,
Rockford, IL, USA) according to the manufacturers’ protocol. The
following oligonucleotides were used as probes in the analyses: IR-
1, sense 59-CTT TAG GCC ATT GAC CTA TAA-39 and antisense
59-TTA TAG GTC AAT GGC CTA AAG-39 (Geier et al., 2005b).
These oligonucleotides were end-labeled using the biotin 39 end
DNA labeling kit (Pierce Biotechnology). Binding reactions con-
sisted of 1= binding buffer, 50 ng/ml poly dIdC, 20 fmol biotin-
labeled DNA and 5 mg nuclear protein in a 20 ml reaction.
Competition experiments included 6 pmol unlabeled oligonucleotide
(300-fold molar excess). Densitometric quantification was per-
formed using Quantity One software (Bio-Rad).
Bile acid quantification
Serum bile acids were measured by RIA using a Bile Acid RIA Kit
(MP Biomedicals, Ilkirch, France) according to the manufacturer’s
specifications.
Statistical analysis
Statistical significance (p-0.05) between control animals and
ob/ob-mice was determined by Student’s t-test. Data represent the
mean"standard deviation.
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